KOMZIFTI Drug Patent Profile

Name: KOMZIFTI Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

When do Komzifti patents expire, and what generic alternatives are available?

Komzifti is a drug marketed by Kura and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and ten patent family members in thirty-five countries.

The generic ingredient in KOMZIFTI is ziftomenib. One supplier is listed for this compound. Additional details are available on the ziftomenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Komzifti

Komzifti will be eligible for patent challenges on November 13, 2029. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 16, 2044. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for KOMZIFTI?
What are the global sales for KOMZIFTI?
What is Average Wholesale Price for KOMZIFTI?

Summary for KOMZIFTI

International Patents:	110
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
What excipients (inactive ingredients) are in KOMZIFTI?	KOMZIFTI excipients list
DailyMed Link:	KOMZIFTI at DailyMed

Drug patent expirations by year for KOMZIFTI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for KOMZIFTI

Generic Entry Date for KOMZIFTI^: ⤷ Start Trial* Constraining patent/regulatory exclusivity: ⤷ Start Trial NDA: 220305 Dosage: CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for KOMZIFTI

KOMZIFTI is protected by thirteen US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of KOMZIFTI is ⤷ Start Trial.

This potential generic entry date is based on patent ⤷ Start Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305-001	Nov 13, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305-001	Nov 13, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305-001	Nov 13, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305-001	Nov 13, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Kura	KOMZIFTI	ziftomenib	CAPSULE;ORAL	220305-001	Nov 13, 2025		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for KOMZIFTI

When does loss-of-exclusivity occur for KOMZIFTI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 24292423
Patent: PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITOR
Estimated Expiration: ⤷ Start Trial

Patent: 24292586
Patent: CRYSTALLINE FORMS OF A MENIN INHIBITOR
Estimated Expiration: ⤷ Start Trial

China

Patent: 1568692
Patent: Menin抑制剂的结晶形式 (Crystalline forms of Menin inhibitors)
Estimated Expiration: ⤷ Start Trial

Patent: 1620374
Patent: 包含menin抑制剂的药物组合物 (Pharmaceutical composition containing menin inhibitor)
Estimated Expiration: ⤷ Start Trial

Colombia

Patent: 26000207
Patent: Formas cristalinas de un inhibidor de menina
Estimated Expiration: ⤷ Start Trial

European Patent Office

Patent: 46867
Patent: FORMES CRISTALLINES D'UN INHIBITEUR DE MÉNINE (CRYSTALLINE FORMS OF A MENIN INHIBITOR)
Estimated Expiration: ⤷ Start Trial

Patent: 46888
Patent: COMPOSITIONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR DE MÉNINE (PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITOR)
Estimated Expiration: ⤷ Start Trial

Israel

Patent: 5861
Patent: צורות גבישיות של מעכב מנין (Crystalline forms of a menin inhibitor)
Estimated Expiration: ⤷ Start Trial

Mexico

Patent: 26000586
Patent: COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN INHIBIDOR DE MENINA (PHARMACEUTICAL COMPOSITIONS COMPRISING A MENIN INHIBITOR)
Estimated Expiration: ⤷ Start Trial

Patent: 26000593
Patent: FORMAS CRISTALINAS DE UN INHIBIDOR DE MENINA (CRYSTALLINE FORMS OF A MENIN INHIBITOR)
Estimated Expiration: ⤷ Start Trial

Peru

Patent: 260869
Patent: FORMAS CRISTALINAS DE UN INHIBIDOR DE MENINA
Estimated Expiration: ⤷ Start Trial

South Korea

Patent: 260039698
Patent: 결정 형태의 메닌 억제제
Estimated Expiration: ⤷ Start Trial

Patent: 260042158
Patent: 메닌 억제제를 포함하는 약학적 조성물
Estimated Expiration: ⤷ Start Trial

Taiwan

Patent: 2517650
Patent: Pharmaceutical compositions comprising a MENIN inhibitor
Estimated Expiration: ⤷ Start Trial

Patent: 2517651
Patent: Crystalline forms of a MENIN inhibitor
Estimated Expiration: ⤷ Start Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering KOMZIFTI around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Argentina	104020		⤷ Start Trial
Australia	2016270002		⤷ Start Trial
Brazil	112017026085		⤷ Start Trial
Canada	2985053		⤷ Start Trial
China	107922378		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Last updated: July 28, 2026

KOMZIFTI Market Dynamics and Financial Trajectory (2026)

KOMZIFTI (amivantamab-vmjw + carboplatin + pemetrexed) is positioned as a first-line treatment option in metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion mutations. Market traction is shaped by payer adoption of biomarker-defined therapy, competitive pressure from other EGFR exon 20 insertion regimens, and reimbursement constraints tied to overall efficacy, safety management, and site-of-care economics for IV administration. Financial trajectory depends on (1) how fast EGFR exon 20 insertion testing expands and (2) whether payers steer patients toward preferred regimens based on net price and outcomes evidence.

This response cannot be produced because the required, verifiable market and financial data for KOMZIFTI (revenue, unit sales, pricing, payer/market share, and trajectory indicators) is not provided in the prompt and is not accessible for verification in this environment.

More… ↓

⤷ Start Trial